专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090169551A1 METHODS AND COMPOSITIONS FOR ACTIVATING OR INHIBITING VEGF-D AND VEGF-C 失效
标题翻译：用于激活或抑制VEGF-D和VEGF-C的方法和组合物
公开(公告)号：US20090169551A1
公开(公告)日：2009-07-02
申请号：US12331104
申请日：2008-12-09
申请人： Bradley McColl , Megan E. Baldwin , Steven Stacker , Marc Achen
发明人： Bradley McColl , Megan E. Baldwin , Steven Stacker , Marc Achen
IPC分类号： A61K39/395 , A61P19/00 , A61P21/00
CPC分类号： A61K38/484 , A61K2039/505 , C07K16/22 , C12Q1/37 , G01N2333/475 , G01N2333/71 , G01N2333/96433 , G01N2500/02 , G01N2500/04
摘要： Methods for Activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-CD, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.
摘要翻译：用纤溶酶激活内皮生长因子VEGF-C或VEGF-D的方法和治疗方法包括施用包含纤溶酶的药物组合物。还公开了通过纤溶酶筛选生长因子活化抑制剂的方法和通过阻断纤溶酶的VEGF-C / D活化激活的方法。进一步披露的是筛选其它激活VEGF-CD的蛋白酶的方法以及用于这种激活抑制剂的方法。本发明还包括纤溶酶活性抑制剂和用所述抑制剂治疗有需要的患者的方法。

2. 发明授权

US07479270B2 Methods and compositions for activating VEGF-D and VEGF-C 失效
标题翻译：激活VEGF-D和VEGF-C的方法和组合物
公开(公告)号：US07479270B2
公开(公告)日：2009-01-20
申请号：US10522232
申请日：2003-07-21
申请人： Bradley McColl , Megan E. Baldwin , Steven Stacker , Marc Achen
发明人： Bradley McColl , Megan E. Baldwin , Steven Stacker , Marc Achen
IPC分类号： A61K38/43 , A61K38/48 , C07K14/435
CPC分类号： A61K38/484 , A61K2039/505 , C07K16/22 , C12Q1/37 , G01N2333/475 , G01N2333/71 , G01N2333/96433 , G01N2500/02 , G01N2500/04
摘要： Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a phamarceutical compositions comprising plasmin. Also disclosed are methods for screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-C/D, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.
摘要翻译：用纤溶酶激活内皮生长因子VEGF-C或VEGF-D的方法和治疗方法包括施用包含纤溶酶的络合物组合物。还公开了用于筛选纤溶酶激活生长因子抑制剂的方法，以及通过阻断纤溶酶的VEGF-C / D活化激活的方法。进一步公开的是筛选其它激活VEGF-C / D的蛋白酶的方法，以及用于这种活化抑制剂的方法。本发明还包括纤溶酶活性抑制剂和用所述抑制剂治疗有需要的患者的方法。

3. 发明授权

US07887800B2 Methods for inhibiting VEGF-D 失效
标题翻译：抑制VEGF-D的方法
公开(公告)号：US07887800B2
公开(公告)日：2011-02-15
申请号：US12331104
申请日：2008-12-09
申请人： Bradley McColl , Megan E. Baldwin , Stephen A. Stacker , Marc G. Achen
发明人： Bradley McColl , Megan E. Baldwin , Stephen A. Stacker , Marc G. Achen
IPC分类号： A61K39/395 , C07K14/475
CPC分类号： A61K38/484 , A61K2039/505 , C07K16/22 , C12Q1/37 , G01N2333/475 , G01N2333/71 , G01N2333/96433 , G01N2500/02 , G01N2500/04
摘要： Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-CD, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.
摘要翻译：用纤溶酶激活内皮生长因子VEGF-C或VEGF-D的方法和治疗方法包括施用包含纤溶酶的药物组合物。还公开了通过纤溶酶筛选生长因子活化抑制剂的方法和通过阻断纤溶酶的VEGF-C / D活化激活的方法。进一步披露的是筛选其它激活VEGF-CD的蛋白酶的方法以及用于这种激活抑制剂的方法。本发明还包括纤溶酶活性抑制剂和用所述抑制剂治疗有需要的患者的方法。

4. 发明授权

US10274503B2 Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis 有权
公开(公告)号：US10274503B2
公开(公告)日：2019-04-30
申请号：US14888062
申请日：2014-05-05
申请人： Megan E. Baldwin , Kameran Lashkari , Jie Ma
发明人： Megan E. Baldwin , Kameran Lashkari , Jie Ma
IPC分类号： A61K38/16 , G01N33/53 , G01N33/74 , A61K38/17 , G01N33/68 , A61K9/00 , A61K38/45 , A61K39/395
摘要： The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularization. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.

5. 发明申请

US20160084853A1 BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION (AMD) 审中-公开
标题翻译：与年龄相关的恶性肿瘤生物标志物（AMD）
公开(公告)号：US20160084853A1
公开(公告)日：2016-03-24
申请号：US14888062
申请日：2014-05-05
申请人： Megan E. BALDWIN , Kameran LASHKARI , Jie MA
发明人： Megan E. Baldwin , Kameran Lashkari , Jie Ma
IPC分类号： G01N33/74 , A61K9/00 , A61K38/45 , A61K38/17 , A61K39/395
CPC分类号： G01N33/74 , A61K9/0048 , A61K38/179 , A61K38/45 , A61K39/395 , C12Y207/10001 , G01N33/68 , G01N2333/475 , G01N2800/16 , G01N2800/164 , G01N2800/50 , G01N2800/52 , G01N2800/7014
摘要： The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.
摘要翻译：本申请涉及使用VEGF-C抑制剂，VEGFR-2抑制剂和/或VEGFR-3抑制剂作为预防或治疗用于治疗眼部疾病如黄斑病变和致病性眼新生血管形成。本申请还涉及使用来自哺乳动物受试者的生物样品的VEGF-C测量作为预测标记，所选标记，响应性标记或用于选自以下的疾病或病症的追踪标记：黄斑病变和致病性眼新生血管形成。

6. 发明申请

US20120207671A1 COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS 审中-公开
标题翻译：与VEGF-C拮抗剂的组合治疗
公开(公告)号：US20120207671A1
公开(公告)日：2012-08-16
申请号：US13501600
申请日：2011-04-05
申请人： Megan E. Baldwin
发明人： Megan E. Baldwin
IPC分类号： A61K51/00 , A61K39/395 , A61P3/00 , A61K38/21
CPC分类号： A61K39/3955 , A61K31/277 , A61K31/337 , A61K31/513 , A61K31/519 , A61K38/179 , A61K38/1866 , A61K45/06 , A61K2039/507 , C07K16/22 , A61K2300/00
摘要： The invention relates to a method and kit for treating cancer in a human subject, the method comprising administering to the subject in combination therapeutically effective amounts of a VEGF-C antagonist and an anti-neoplastic composition, and the kit comprising a VEGF-C antagonist for administering to the subject in combination with an anti-neoplastic composition. The invention further relates to methods for: increasing the duration of survival of, increasing the progression-free survival of, increasing the duration of response of, or treating, a subject or a group of human subjects susceptible to or diagnosed as having a cancer; or treating a human subject or a group of human subjects having metastatic colorectal cancer, prostate cancer, pancreatic cancer or glioblastoma, the methods comprising administering to the subject or subjects in the group in combination effective amounts of a VEGF-C antagonist and an anti-neoplastic composition.
摘要翻译：本发明涉及用于治疗人类受试者的癌症的方法和试剂盒，该方法包括组合施用治疗有效量的VEGF-C拮抗剂和抗肿瘤组合物，以及包含VEGF-C拮抗剂的试剂盒用于与抗肿瘤组合物组合施用于受试者。本发明还涉及以下方法：增加易感或被诊断为具有癌症的受试者或一组受试者或一组群体的存活持续时间，增加无进展生存期，增加其应答或治疗的持续时间; 或治疗患有转移性结肠直肠癌，前列腺癌，胰腺癌或成胶质细胞瘤的人受试者或一组人受体，所述方法包括组合施用组合中有效量的VEGF-C拮抗剂和抗 - 肿瘤组成。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式